Zensun provides innovative therapeutics for major diseases.
Zensun’s proprietary core science is based on our intensive research of receptor tyrosine kinases (RTKs), specifically the ErbB receptor family and downstream-activated signaling pathways. We believe that our breakthrough discoveries will revolutionize heart failure treatment.
Receptor tyrosine kinases are cell surface proteins that regulate many essential cell type-specific functions, particularly cell growth, proliferation, and survival. The ErbB family of RTKs includes 4 distinct receptors (ErbB1, ErbB2, ErbB3 and ErbB4), each of which shares sequence similarity with a protein encoded by the chicken retroviral oncogene v-erbB. Insufficient ErbB signaling in humans is associated with the development of neurodegenerative diseases, such as multiple sclerosis and Alzheimer’s disease. The ERBB4/2 signaling pathway is closely associated with heart failure.
After decades of research in the ErbB signaling system, Zensun brings new visions into the links of this signaling system and some important diseases.
We have discovered that Neuregulin-1 regulated ErbB4/2 heterodimerization plays a critical role in cardiovascular development and adult heart function maintenance. This discovery directly leads to our innovative anti-heart failure drug Neucardin®.
In recent years, Zensun's research has expanded from focusing on heart failure to general organ failure. ZS-06 and ZS-07 developed by the company have been shown in preclinical trials to significantly improve the symptoms of various diseases related to organ function decline/failure, such as functional constipation and Alzheimer's disease.